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BACKGROUND: Use of snus, a smokeless tobacco product, is increasing in Scandinavia. Strenuous physical activity is associ-
ated with an acute increase in high-sensitivity cardiac troponin (hs-cTn) concentrations. Current smoking is associated with 
lower hs-cTn, but whether this also holds true for smokeless tobacco and whether tobacco affects the hs-cTn response to 
exercise remain unknown.
METHODS AND RESULTS: We measured hs-cTnI and hs-cTnT concentrations in 914 recreational athletes before and 3 and 
24 hours after a 91-km bicycle race. Self-reported snus tobacco habits were reported as noncurrent (n=796) and current 
(n=118). The association between snus use and change in log-transformed hs-cTnI and hs-cTnT concentrations (ie, the dif-
ferences between concentrations at baseline and 3 hours and 24 hours ) were assessed by multivariable linear regression 
analysis. Concentrations of hs-cTn at baseline were lower in current than in noncurrent snus users (hs-cTnI median, 1.7 ng/L; 
Q1 to Q3: 1.6–2.3 versus 2.0 ng/L; Q1 to Q3: 1.6–3.2 [P=0.020]; and hs-cTnT: median, 2.9 ng/L, Q1 to Q3: 2.9–3.5 versus 
2.9 ng/L, Q1 to Q3: 2.9–4.3 [P=0.021]). In fully adjusted multivariable models, use of snus was associated with lower change 
in hs-cTn concentrations from baseline to 3 hours (hs-cTnI: −29% [P=0.002], hs-cTnT: −18% [P=0.010]) and 24 hours (hscTnI: 
−30% [P=0.010], hs-cTnT −19%, [P=0.013]).
CONCLUSIONS: Resting hs-cTn concentrations are lower and the exercise-induced cardiac troponin response is attenuated in 
current users of smokeless tobacco compared with nonusers. Further insight into the pathophysiological processes underly-
ing the attenuated cardiac troponin response to exercise in tobacco users is needed.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT02166216.
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Strenuous exercise is associated with an acute and transient increase in circulating cardiac tro-ponin (cTn) concentrations.1 Although elevated 
concentrations of cTn in healthy individuals following 
strenuous activity in most cases is considered to be 
a benign phenomenon, the underlying pathophysio-
logical mechanisms and clinical relevance remain un-
clear.1–4 The dominating theory for the exercise-related 
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cTn response, however, is release of loosely bound tro-
ponin from a rapidly releasable pool combined with a 
reversible increase in membrane permeability.5,6
A broad range of smokeless tobacco products are 
used by >300  million adults around the world, and 
Swedish snus is the dominating smokeless tobacco 
in Scandinavia. In contrast to the marked decline in 
tobacco smoking, the consumption of snus has in-
creased both in Scandinavia and in the United States 
during the past decades.7,8 Despite no demonstrable 
effect of snus use on exercise performance, the use 
of smokeless tobacco is common and also increasing 
among elite and recreational athletes.9 It is well docu-
mented that tobacco smoking is associated with an 
increased incidence of cardiovascular disease.10 The 
association between snus tobacco and cardiovascular 
risk, however, remains unclear. Raised blood pressure 
and heart rate are described as acute hemodynamic 
effects of snus,11 and some data suggest that quitting 
snus after a myocardial infarction is associated with 
reduced mortality.12 However, no increased risk of non-
fatal ischemic heart disease has been found among 
Swedish snus users.13
Stable, low-grade elevation in high-sensitivity cTn 
(hs-cTn), even within the normal concentration range, 
is associated with increased risk of nonfatal and fatal 
cardiovascular events.14,15 Surprisingly, lower concen-
trations of hs-cTn in smokers have been demonstrated 
in 2 large population-based cohorts.16,17 However, the 
influence of smokeless tobacco on baseline and exer-
cise-induced concentrations is unknown. We hypothe-
sized that snus use is inversely associated with hs-cTn 
concentrations in the resting state and an attenuated 
hs-cTn response after strenuous exercise. To test 
these novel hypotheses, we assessed the association 
between snus use and circulating levels of hs-cTnI and 
hs-cTnT at rest and following strenuous exercise in a 
large cohort of healthy, trained individuals.
METHODS
The data that support the findings of this study are 
available from Dr Stein Ørn on reasonable request.
Study Overview and Participants
This is a substudy of NEEDED (North Sea Race 
Endurance Exercise Study) 2014. Details of the NEEDED 
design and the principal results have been previously 
reported.1 In brief, this is a prospective observational 
study of the biomarker response in healthy recreational 
cyclist participating in a 91-km bicycle race (North Sea 
Race) in Norway. Race participants without previous 
known cardiac disease, hypertension, and diabetes 
mellitus were invited to participate in the study. Study 
recruitment was performed with an electronic form dis-
tributed through the official website of the North Sea 
Race (www.nords jorit tet.no). The Regional Committee 
for Medical Research Ethics approved the study, and all 
participants provided informed written consent.
Baseline Data
Clinical examinations were performed in a standard-
ized manner and included height, weight, blood pres-
sure, and resting ECG. Information on health, lifestyle, 
fitness, and training-related items were gathered from 
self-reported electronic questionnaires. Data on snus 
use and cigarette smoking were also collected via the 
electronic questionnaire. The questionnaire was sub-
mitted before the race.
Blood Sampling Procedures and 
Biochemical Assays
As previously reported, samples of nonfasting ve-
nous blood were collected 24 hours before the race 
CLINICAL PERSPECTIVE
What Is New?
• In this cohort of healthy, trained individuals, we 
demonstrate lower concentrations of circulat-
ing cardiac troponin I and cardiac troponin T in 
users of snus, a moist oral tobacco product in 
the resting state.
• Current snus users had a smaller increase in 
cardiac troponin concentrations 3 and 24 hours 
postexercise compared with noncurrent users 
of snus.
What Are the Clinical Implications?
• The increasing use of alternative tobacco prod-
ucts is a public health concern, and the current 
study demonstrates that moist oral tobacco 
may impact the release or degradation of car-
diac troponins.
• Use of smokeless tobacco is associated with 
lower circulating cardiac troponin concentra-
tions both in the resting state and after exercise, 
and tobacco use should be taken into account 
when interpreting cardiac troponin test results.
Nonstandard Abbreviations and Acronyms
cTn cardiac troponin
cTnI cardiac troponin I
cTnT cardiac troponin T
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(baseline) and at 3 and at 24 hours following the race. 
The serum samples were stored at 4°C and trans-
ported to Stavanger University Hospital, Norway. hs-
cTnI concentrations were analyzed within 24  hours 
with the Abbott Diagnostics STAT High Sensitive 
Troponin assay on Architect i2000SR (Abbott 
Diagnostics), with a lower detection limit of 1.6 ng/L. 
Additional serum was frozen at −80°C and shipped 
to Haukeland University Hospital, Bergen, Norway, 
for measurement of hs-cTnT on a Cobas e602 device 
(Roche Diagnostics), with a level of blank of 3 ng/L 
and lower detection limit of 5 ng/L. During the period 
in which the NEEDED samples were analyzed, the 
cTnT assay had a total analytical coefficient of varia-
tion (CVA) of 13% at 4.5 ng/L, 3.6% at 18 ng/L, and 
2.1% at 93 ng/L. The cTnI assay had a total CVA of 
10% at 6 ng/L, 7% at 27 ng/L, and 5% at 140 ng/L. 
Information concerning the fraction of deltas that 
were higher than the reference change value are pre-
sented in Data S1.
Statistical Analysis
Means and SDs were reported for continuous varia-
bles with a symmetric distribution, while median and 
25th to 75th percentile were reported for variables 
with a markedly skewed distribution. We used the 
Shapiro–Wilk test to test for normality. Numbers and 
percentages were used to report frequencies. The 
Student t test, Mann–Whitney U test, chi-square test, 
or the Fisher exact test was used for comparison of 
groups, as appropriate. A P value of <0.05 was con-
sidered significant. To assess the relationship be-
tween use of smokeless tobacco and the troponin 
increase, the delta values were used in multiple linear 
regression analysis. Potential confounding variables 
were selected a priori, based on factors known to in-
fluence cardiovascular risk and/or exercise-induced 
cTn release.
Model 1 was unadjusted, model 2 was adjusted 
for sex and age, model 3 was adjusted for model 
2 and systolic blood pressure, body mass index, 
low-density lipoprotein cholesterol, and estimated 
glomerular filtration rate, and model 4 was adjusted 
for the same variables as in model 3 but also race 
duration and resting heart rate. Residual plots were 
deemed satisfactory after ln transformation of the 
dependent variables. Missing data attributable to a 
negative delta value were <5% in the smokeless to-
bacco group at any time, while the nonsmokeless to-
bacco group had 0.3%/2.5% missing for delta cTnI at 
0 to 3 hours/0 to 24 hours, and 2.3%/5.4% for delta 
cTnT at 0 to 3 hours/0 to 24 hours. To evaluate the ro-
bustness of our findings and to assess consistency, 
we also performed all analyses using the absolute 
cTn concentrations at 3 and 24  hours rather than 
the delta value as the dependent variable in the full 
sample. For the statistical analysis, the software pro-
grams SPSS version 24 (SPSS Inc) and GraphPad 
Prism version 8 (GraphPad Software) were used.
RESULTS
Characteristics at Baseline
Overall, 914 race participants with cTn results and 
data concerning snus use were included in the study; 
711 (78%) were men and the median age was 46.7 
years (quartile 1 to quartile 3 [Q1 to Q3] 40.2–52.4 
years). Among the participants, 118 (13%) were cur-
rent snus users and 794 (87%) were noncurrent 
users of snus. Current users of snus were younger 
and had higher estimated glomerular filtration rate 
than nonusers. The prevalence of smoking habits dif-
fered according to snus use. Current users of snus 
were more likely to be former and current smokers 
than never users. However, training history and race 
performance did not differ between current and non-
current users of snus (Table 1).
Associations Between Snus Use and  
hs-cTnI and hs-cTnT at Baseline
Concentrations of cTn in the resting state differed ac-
cording to snus use (Figure). In unadjusted analyses, 
current snus use was associated with significantly 
lower concentrations of hs-cTnI (current users of snus 
versus noncurrent: median, 1.7 ng/L; Q1 to Q3: 1.6–2.3 
versus 2.0 ng/L; Q1 to Q3: 1.6–3.2; P=0.020) and hs-
cTnT (current users of snus versus noncurrent: median, 
2.9 ng/L; Q1 to Q3: 2.9–3.5 versus 2.9 ng/L; Q1 to Q3: 
2.9–4.3; P=0.021) before the race.
Association Between Snus Use and the 
Magnitude of the cTn Response to Exercise
Concentrations of cTn 3 and 24 hours after exercise 
also differed according to snus use (Figure). The 
change in concentrations of hs-cTnI from baseline 
to 3  hours postexercise (median, 35.4  ng/L; Q1 to 
Q3: 23.2–76.1 ng/L) was significantly lower in current 
than noncurrent users of snus (median, 50.2  ng/L; 
Q1 to Q3: 31.1–87.9  ng/L [P=0.001]). A similar pat-
tern was observed for the change in concentrations 
of hs-cTnT from baseline to 3  hours postexercise: 
concentrations were lower in current users of snus 
(median, 25.9 ng/L; Q1 to Q3: 16.5–43.0 ng/L) than 
in noncurrent users (median 32.3  ng/L; Q1 to Q3: 
21.6–50.1  ng/L [P=0.010]). The inverse association 
between current snus use and the change in con-
centrations from baseline to 24  hours following the 
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Tables 2 and 3 show the relationship between snus 
use and circulating concentrations of delta hs-cTnI and 
hs-cTnT at 3 and 24 hours in a series of multivariable 
models.
After adjustment for potentially cofounding fac-
tors, the inverse association between current snus 
tobacco use and change in hs-cTnI concentrations 
from baseline to 3 hours postexercise remained sig-
nificant (β coefficient, −0.31; 95% CI, −0.49 to −0.13 
[P=0.001]). After additional adjustment for race du-
ration and heart rate, the relationship between snus 
tobacco use and hs-cTnI was not markedly changed. 
Furthermore, the change in hs-cTnI concentrations 
between baseline and 24 hours were 30% lower in 
current users of snus compared with noncurrent snus 
users in fully adjusted models (P=0.010) (Table  2; 
multivariable model 3 and 4).
Compared with noncurrent users of snus, the 
change in hs-cTnT levels from baseline to 3  hours 
was 18% lower in current snus users in fully adjusted 
models (P=0.010). The change in hs-cTnT values from 
baseline to 24  hours was also significantly lower in 
users of snus compared with noncurrent users after 
adjusting for conventional risk factors (β coefficient, 
−0.21; 95% CI, −0.36 to −0.05 [P=0.009]) and after 
adding race duration and resting heart rate to the 
model (β coefficient, −0.19; 95% CI, −0.34 to −0.04; 
P=0.013) (Table 3).
Table 1. Baseline Characteristics According to Snus Status
Variable
Noncurrent Snus Users 
n=796
Current Snus Users 
n=118 P Value
Baseline characteristics
Men, No. (%) 609 (76.5) 102 (86.4) 0.015
Age, y 47.0 (41.1–53.0) 43.1 (36.5–49.6) <0.001
Weight, kg 82.1 (74.5–89.3) 81.1 (73.4–90.2) 0.798
Body mass index, kg/m2 25.3 (23.8–27.4) 25.1 (23.5–27.5) 0.564
Waist circumference 86.0 (80.0–92.9) 84.8 (80.0–91.0) 0.508
Systolic blood pressure, mm Hg 136.5 (127.0–148.0) 135.0 (120.0–145.0) 0.153
Diastolic blood pressure, mm Hg 80.0 (74.0–86.0) 79.0 (73.0–85.0) 0.691
Resting heart rate 59.0 (53.0–66.0) 61 (52–67) 0.545
Medical history
Family history of cardiovascular disease, No. (%)* 151 (19.5) 31 (26.3) 0.045
Never smoker, No. (%) 519 (66.8) 40 (33.9)
Former smoker, No. (%) 248 (31.9) 64 (54.2)
Current smoker, No. (%) 10 (1.3) 3 (2.5) <0.001
Blood tests
eGFR, mL/min per 1.73 m2 91.0 (82.2–99.8) 94.1 (84.4–103.5) 0.003
LDL cholesterol, mmol/L 3.2 (2.6–3.7) 3.3 (2.7–3.8) 0.291
HDL cholesterol, mmol/L 1.5 (1.3–1.7) 1.5 (1.3–1.8) 0.970
CRP, mg/L 0.8 (0.4–1.4) 0.6 (0.3–1.0) 0.004
Troponin measurements
cTnI, baseline, ng/L 2.0 (1.6–3.2) 1.7 (1.6–2.3) 0.020
Delta cTnI, 3 h postexercise-baseline, ng/L 50.2 (31.1–87.9) 35.4 (23.2–76.1) 0.001
Delta cTnI, 24 h postexercise-baseline, ng/L 7.6 (4.0–16.7) 5.7 (2.7–12.7) 0.009
cTnT, baseline, ng/L 2.9 (2.9–4.3) 2.9 (2.9–3.5) 0.021
Delta cTnT, 3 h postexercise-baseline, ng/L 32.3 (21.6–50.1) 25.9 (16.5–43.0) 0.010
Delta cTnT, 24 h postexercise-baseline, ng/L 6.4 (3.4–11.1) 5.4 (2.3–10.0) 0.058
Training history
No. of endurance competitions in the past 5 y 7.0 (3.0–15.0) 5.0 (3.0–10.0) 0.075
MET, h/wk† 51.2 (30.8–80.4) 49.8 (28.9–80.0) 0.454
Race performance
Race duration, h 3.8 (3.4–4.3) 3.7 (3.4–4.1) 0.427
CRP indicates C-reactive protein; cTnI, cardiac troponin I; cTnT, cardiac troponin T; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; and MET, metabolic equivalent.
*Women: first-degree relative with cardiovascular disease before the age of 65, men: first-degree relative with cardiovascular disease before the age of 60.
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Sensitivity Analyses
The inverse association between current snus 
use and cTn remained significant in analyses with 
absolute troponin concentrations at 3 and 24 hours 
in the total sample postexercise as the depend-
ent variable. In fully adjusted models, users of snus 
had lower concentrations of cTn both at 3  hours 
Figure. Concentrations of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity 
cardiac troponin T (hs-cTnT) at baseline and at 3 and 24 hours following the race.
Median with 25th to 75th percentile. Red boxes represent current users of snus and blue boxes 
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(hs-cTnI: β coefficient, −0.28; 95% CI, −0.44 to −0.11 
[P=0.001] and hs-cTnT: β coefficient, −0.17; 95% CI, 
−0.29 to −0.05 [P=0.005]) and 24 hours (hs-cTnI: β 
coefficient, −0.23; 95% CI, −0.43 to −0.04 [P=0.020] 
and hs-cTnT: β coefficient, −0.14; 95% CI, −0.26 to 
−0.02 [P=0.019]) postexercise, compared with non-
current snus users.
Despite the low number of current smokers in our 
sample (n=13), we also performed a sensitivity analysis 
excluding all current smokers to eliminate the potential 
confounding effects of current smoking. This did not 
change the results (Tables S1 and S2).
DISCUSSION
The new and important information derived from the 
current study is that tobacco consumption is not only 
associated with lower cTn concentrations in the rest-
ing state but also reduces the exercise-induced cTn 
response. Specifically, the current study demonstrates 
that users of snus tobacco have both lower circulat-
ing concentrations of hs-cTnI and hs-cTnT in the rest-
ing state and a smaller increase in concentrations of 
cTn following termination of strenuous exercise than 
nonusers of snus. The longitudinal experimental de-
sign, which allows the participants to serve as their 
own controls, the consistent results for both hs-cTnI 
and hs-cTnT in a large cohort of healthy individuals, 
and measurements of troponins at baseline and 3 and 
24 hours after termination of exercise support the va-
lidity of our findings. Although the clinical applicability 
of the results is unknown, it signals that smokeless to-
bacco use may confound the association between cTn 
and cardiovascular health.
Association Between Smokeless Tobacco 
Use and cTn Concentrations
In the current study, we demonstrate for the first time 
an association between current snus tobacco use 
and lower cTn concentrations in the resting state. This 
lends further support to the validity of the finding of an 
inverse association between tobacco smoking and cTn 
observed in the population-based setting.16,17
An increase in concentrations of cTn following in-
tense exercise is commonly observed.2 Activity-related 
changes in serum enzymes have been known for sev-
eral decades,18,19 and, in line with these observations, 
exercise-induced troponin increase has traditionally 
been considered a benign and physiological phenom-
enon. However, recent observations demonstrating 
associations between the magnitude of postexer-
cise troponin response and cardiovascular disease 
and outcome20,21 challenge this concept. Moreover, 
it highlights that more detailed information is needed 
Table 2. Association Between Snus Use and Concentrations of Delta cTnI
Β Coefficient (95% CI)
Model 1 Model 2 Model 3 Model 4
Delta hs-cTnI 3 h—baseline
Current snus −0.28 (−0.46 to −0.10), 
P=0.003
−0.33 (−0.51 to −0.14), 
P=0.001
−0.31 (−0.49 to −0.13), 
P=0.001
−0.29 (−0.47 to −0.11), 
P=0.002
Delta hs-cTnI 24 h—baseline
Current snus −0.38 (−0.62 to −0.15), 
P=0.002
−0.36 (−0.59 to −0.12), 
P=0.003
−0.32 (−0.56 to −0.09), 
P=0.007
−0.30 (−0.54 to −0.07), 
P=0.010
Model 1 unadjusted; model 2 adjusted for sex and age; model 3 adjusted for the same variables in model 2 but also systolic blood pressure, body mass index, 
low-density lipoprotein cholesterol, and estimated glomerular filtration rate; and model 4 adjusted for the same variables as in model 3 but also race duration 
and resting heart rate. cTnI indicates cardiac troponin I; and hs-cTnI, high-sensitivity cardiac troponin I.
Table 3. Association Between Snus Use and Concentrations of Delta cTnT
Β Coefficient (95% CI)
Model 1 Model 2 Model 3 Model 4
Delta hs-cTnT 3 h—baseline
Current snus −0.17 (−0.31 to −0.03), 
P=0.019
−0.21 (−0.35 to −0.06), 
P=0.005
−0.20 (−0.34 to −0.05), 
P=0.008
−0.18 (−0.32 to −0.04), 
P=0.010
Delta hs-cTnT 24 h—baseline
Current snus −0.20 (−0.36 to −0.04), 
P=0.015
−0.23 (−0.39 to −0.08), 
P=0.004
−0.21 (−0.36 to −0.05), 
P=0.009
−0.19 (−0.34 to −0.04), 
P=0.013
Model 1 unadjusted; model 2 adjusted for sex and age; model 3 adjusted for the same variables as in model 2 but also systolic blood pressure, body mass 
index, low-density lipoprotein cholesterol, and estimated glomerular filtration rate; and model 4 adjusted for the same variables as in model 3 but also race 
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on determinants of the magnitude of transient eleva-
tions of cTn following exercise. In the current study, we 
add to the existing knowledge by providing data on 
the associations between snus tobacco and the exer-
cise-induced troponin response. Our results indicate 
that substances in tobacco may modulate the acute 
release and/or degradation of cTn in the exercise-in-
duced release setting.
Potential Mechanisms
The use of nicotine is high and increasing within the field 
of sports,9 and from 2012 nicotine has been on the World 
Anti-Doping Agency´s Monitoring Program. Nicotine 
is one of the main active substances in tobacco, and 
the total nicotine exposure is similar for cigarette smok-
ers and users of snus tobacco.22,23 Psychostimulatory, 
sympathetic nervous system, and cardiovascular ef-
fects are observed following nicotine delivery.24 The evi-
dence for performance-enhancing effects of nicotine in 
sports, however, is low,9 and race duration did not differ 
between users and nonusers of snus in our analyses. 
In a prospective study of patients with coronary artery 
disease, nicotine patch therapy and subsequent higher 
nicotine concentrations used to promote smoking ces-
sation improved myocardial perfusion.25
Although the performance-enhancing effects 
of nicotine are unlikely to explain the differences 
observed, higher myocardial perfusion as a con-
sequence of nicotine use could be a possible mech-
anism for lower circulating concentrations of cTn in 
snus users.
Nicotine effects on degradation and clearance of 
cTn could be another explanation for lower concentra-
tions of cTn in users of snus. Katrukha et al26 recently 
demonstrated the degradation of cTnT by the coag-
ulation enzyme thrombin in an experimental study. 
Tobacco smoking is associated with an increase in 
prothombotic factors.27 Tissue factor, which initiates 
formation of platelet-dependent thrombin, has been 
found to be higher in cigarette smokers.28 Less is 
known about the effects of snus on circulating markers 
of thrombogenesis; however, significantly increased 
thrombin has been seen after adding nicotine or co-
tinine to platelet-rich plasma of nonsmokers.29 Given 
this, increased thrombin-mediated proteolysis of cTn 
might be one possible mechanism for lower cTn con-
centrations in current users of snus.
Associations between smoking and improved 
short-term outcomes have been described for several 
cardiovascular disorders.30–32 The mechanisms un-
derlying the “smokers’ paradox” are unknown, but a 
possible explanation could be that tobacco protects 
myocytes by preconditioning.31,32 Whether this ap-
parently cardioprotective effect of smoking also holds 
true for snus is unknown. Furthermore, if the smokers’ 
paradox is the result of biological effects of tobacco or 
could be explained by selection and/or unmeasured 
bias is an ongoing discussion.30,33
Strengths and Limitations
The large sample size, quantification of troponin 
with 2 high-sensitive troponin assays, and multi-
ple troponin sampling times are strengths of this 
study. This study also has several limitations. First, 
because data on tobacco habits are self-reported 
by the participants and not validated by biochemi-
cal tests, underestimating may have happened. 
However, the correlation between self-reported to-
bacco/nontobacco use and nicotine exposure, as-
sessed by blood cotinine and nicotine, has been 
shown to be high.34 Second, unknown factors as-
sociated with snus use could theoretically explain 
our findings. However, the experimental design in 
which participants served as their own controls and 
measurement of troponin at 3 different time points 
in each study patient reduce the potential for resid-
ual confounding. Third, our study includes a White 
cohort and the sample mainly included snus-using 
men. The findings may not be generalizable to indi-
viduals of other ethnic groups or to women. Fourth, 
cardiac imaging data may have provided better un-
derstanding of the mechanisms underlying the dif-
ference in cTn concentrations. Finally, although the 
current findings suggest that smokeless tobacco 
use should be taken into account when interpreting 
resting and postexercise cTn values, it remains un-
clear whether smokeless tobacco use impacts the 
prognostic value of cTn measurements. Prespecified 
follow-up studies to assess the prognostic value of 
the exercise-induced cTn response are planned 5, 
10, and 20 years following inclusion.
CONCLUSIONS
The findings from the present prospective observa-
tional study of recreational cyclist participating in a 
91-km bicycle race demonstrate lower resting con-
centrations of hs-TnI and hs-cTnT in healthy, trained 
snus users than in nonusers. Significant differences 
between users and nonusers of snus were also ob-
served in hs-cTn concentrations 3 and 24 hours pos-
trace. Moreover, use of snus was associated with a 
lower hs-cTnI and hs-cTnT response following stren-
uous exercise. The current results, combined with 
data from prior reports observing an inverse associa-
tion between cigarette smoking and concentrations 
of cTn, suggest that the effect is real and underscore 
the need for further experimental research exploring 
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Information concerning the fraction of deltas that were higher than the reference 
change value 
The fraction of delta values that are higher than the reference change value, may be important 
for the interpretation of the results. We have earlier described the 6-hour RCVs for healthy 
individuals in a steady-state 35.  In this study participants were sampled during morning hours 
(similar time of the day as the North Sea Race), and the 6-hour RCV includes analytical, 
within subject biological and diurnal (cTnT) variation. Analytical variation in the study is 
similar to the one obtained when the NEEDED samples were analyzed (see above). 
Accordingly, we evaluated the deltas seen during the NEEDED study towards the 6-hour 
positive RCVs (95% CI) for cTnT (22%) and cTnI (Abbott) (64%) as was demonstrated in 
the biological variation study.  
Using this RCV data we found the following: 
Three hours after the North Sea Race 906/913 (99.2%) and 894/897 = 99.7% of participants 
increased their concentrations above the RCV limit for cTnI (64%) and cTnT (22%), 
respectively. There was no difference between the snus and the non-snus groups. For cTnI: 1 
participant in the snus (0.8%) vs. 6 participants (0.8%) in the non-snus group showed cTnI 
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and 2 subjects in the non-snus (0.3%) showed cTnT increase below 22% (p-value for 
difference 0.34). 
Twenty-four hours after the North Sea Race 833/914 (91.1%) and 849/906 (93.7%) of 
participants increased their concentrations above the RCV limit for cTnI (64%) and cTnT 
(22%), respectively. There was no difference between the snus and non-snus groups. For 
cTnI: 15 participants in the snus (12.7%) vs 66 participants (8.3%) in the non-snus group 
showed cTnI increase less than 64% (p-value for difference 0.12). For cTnT: 11 subjects in 
the snus (9.4%) and 46 subjects in the non-snus (5.8%) showed cTnT increase less than 22% 
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Table S1. Association between snus use and concentrations of delta cTnI, smokers 
(n=13) excluded.  
B (95% CI) 
Model 1 Model 2 Model 3 Model 4 
Delta Hs-cTnI 3 hours - baseline 
Current snus -0.32 (-0.50 to -0.14),
p=0.001 
-0.36 (-0.54 to -0.17),
p<0.001 
-0.34 (-0.52 to -0.15),
p<0.001 
-0.32 (-0.50 to -0.14),
p=0.001 
Delta Hs-cTnI 24 hours – baseline 
Current snus -0.42 (-0.66 to -0.18),
p=0.001 
-0.39 (-0.63 to -0.15),
p=0.001 
-0.35 (-0.59 to -0.12),
p=0.004 
-0.34 (-0.57 to -0.10),
p=0.005 
Model 1 unadjusted; model 2 adjusted for sex, age; model 3 adjusted for model 2 and 
systolic blood pressure, body mass index, low-density lipoprotein cholesterol, and estimated 
glomerular filtration rate; model 4 adjusted for the same variables as in model 3 but also 
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Table S2. Association between snus use and concentrations of delta cTnT, smokers 
(n=13) excluded.  
B (95% CI) 
Model 1 Model 2 Model 3 Model 4 
Delta Hs-cTnT 3 hours - baseline 
Current snus -0.20 (-0.34 to -0.05),
p=0.008 
-0.23 (-0.37 to -0.08),
p=0.002 
-0.21 (-0.36 to -0.07),
p=0.004 
-0.21 (-0.35 to -0.06),
p=0.004 
Delta Hs-cTnT 24 hours - baseline 
Current snus -0.23 (-0.39 to -0.06),
p=0.007 
-0.26 (-0.41 to -0.10),
p=0.001 
-0.23 (-0.39 to -0.07),
p=0.004 
-0.22 (-0.37 to -0.06),
p=0.006 
Model 1 unadjusted; model 2 adjusted for sex, age; model 3 adjusted for model 2 and 
systolic blood pressure, body mass index, low-density lipoprotein cholesterol, and estimated 
glomerular filtration rate; model 4 adjusted for the same variables as in model 3 but also 
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